Novartis AG

NVS
NYSE
Last Updated: 8/16/2022 6:37:40 AM
Price
85.38
Changes
-0.30
% Change
-0.35
Volume
1402381
52 Week
High
95.17
52 Week
Low
79.09
About Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Novartis AG Company Details
CEO:   Joseph Jimenez
Country:   CH
Industry:   Drug Manufacturers—General
Website:   https://www.novartis.com
Exchange:   New York Stock Exchange
IPO\Launch Date:   2001-09-05
Novartis AG Company Executive Details
  Ms. Marie-France Tschudin
  Pres of Novartis Pharmaceuticals
  Dr. James E. Bradner M.D.
  Pres of Novartis Institutes for Biomedical Research
  Mr. Richard Saynor
  Chief Executive Officer of Sandoz
  Ms. Susanne Schaffert Ph.D.
  Pres of Novartis Oncology
  Mr. Robert Weltevreden
  Head of Customer & Technology Solutions

Novartis AG Latest News

4 High-Yield Stocks for Dividend Investors


PPL Corp, Duke Energy Corp, Novartis AG and Carlyle Group Inc. are topping the U.S. market average in terms of dividend yields.


Published on: 2022-08-12 16:02:04

Impact on Symbol / Company: NVS

View News

7 Cheap Biotech Stocks to Buy Now


Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.


Published on: 2022-08-03 16:42:38

Impact on Symbol / Company: NVS

View News

Here's Why Income Investors Should Consider Buying This High-Yield Dividend Stock


Novartis is one of the most dominant pharma companies in the world.


Published on: 2022-08-02 11:00:00

Impact on Symbol / Company: NVS

View News

Valeo Pharma enters commercialization and supply agreement with Novartis Canada for two ophthalmic therapies


Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said it has entered into a commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc for the Canadian commercialization of two innovative ophthalmic therapies. Under the agreement, Valeo becomes the exclusive distributor of XIIDRA (lifitegrast) and SIMBRINZA (brinzolamide / brimonidine tartrate) in Canada, making it responsible for all commercial and medical activities.


Published on: 2022-08-02 08:01:07

Impact on Symbol / Company: NVS

View News

What This FDA Delay Means for Novartis


The FDA defers action on a highly anticipated potential blockbuster drug for cancer.


Published on: 2022-07-21 10:15:00

Impact on Symbol / Company: NVS

View News

11 High-Yield Dividend Aristocrats Perfect For The Coming Recession


Fears of a recession are mounting, with BAC and Deutsche Bank now forecasting a mild downturn in 2023. A recession could even begin by December 2022. Even without a recession Morgan Stanley is confident stocks have 10% lower to fall. If we get a mild recession, stocks could fall 25% more and in a severe recession, 35%.


Published on: 2022-07-20 09:15:00

Impact on Symbol / Company: NVS

View News

Novartis AG (NVS) CEO Vas Narasimhan on Q2 2022 Results - Earnings Call Transcript


Novartis AG (NYSE:NVS ) Q2 2022 Results Conference Call July 19, 2022 8:00 AM ET Company Participants Samir Shah - Global Head, IR Vas Narasimhan - CEO Harry Kirsch - CFO Conference Call Participants Matthew Weston - Credit Suisse Tim Anderson - Wolfe Research Richard Vosser - JP Morgan Emmanuel Papadakis - Deutsche Bank Graham Parry - Bank of America Steve Scala - Cowen Florent Cespedes - Société Générale Emily Field - Barclays Simon Baker - Redburn Kerry Holford - Berenberg Seamus Fernandez - Guggenheim Securities Andrew Baum - Citi Laura Sutcliffe - UBS Keyur Parekh - Goldman Sachs Naresh Chouhan - Intron Health Sarita Kapila - Morgan Stanley Peter Welford - Jefferies Wimal Kapadia - Bernstein Richard Parkes - BNP Paribas Operator Good morning and good afternoon, and welcome to the Novartis Q2 2022 Results Release Conference Call and Live Webcast. Please note that during the presentation, all participants will be a listen-only mode and the conference is being recorded.


Published on: 2022-07-19 13:47:05

Impact on Symbol / Company: NVS

View News

Novartis (NVS) Q2 Earnings Beat, Revenues Miss Estimates


Novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic competition remains a drag.


Published on: 2022-07-19 12:23:09

Impact on Symbol / Company: NVS

View News

Novartis Posts Mixed Q2 Earnings, Expects Improved Earnings At Sandoz


Novartis AG (NYSE: NVS) has reported a core EPS of $1.56 in Q2 FY22 compared to $1.66 a year ago, beating the consensus of $1.52. Net sales were $12.78 billion, down 1% Y/Y or up 5% at constant currency (CC), missing the consensus of $13.01 billion.


Published on: 2022-07-19 06:08:02

Impact on Symbol / Company: NVS

View News

Novartis no longer expects earnings decline at under-review Sandoz unit


Swiss drugmaker Novartis said earnings at its Sandoz unit, the maker of cheap generic drugs that might be put up for sale, would likely be flat this year, no longer expecting a decline, and added the strategic review was progressing as planned.


Published on: 2022-07-19 01:20:00

Impact on Symbol / Company: NVS

View News

With Brighter Outlook, Generics Could Be Ripe for Investment


Of the top 10 generic drugmakers in 2021, only one scored an increase in share price during the past year. It was Sun Pharmaceutical Industries Ltd.


Published on: 2022-07-18 16:26:28

Impact on Symbol / Company: NVS

View News

Novartis debuted its first integrated sustainability and finance report this year — more companies are likely to follow suit


The global pharmaceutical company, Novartis, released its first-ever integrated social impact report. The report connects sustainability goals and business objectives.


Published on: 2022-07-06 15:09:03

Impact on Symbol / Company: NVS

View News

Grow your Money

We helps you in understanding the science behind growing the money, which will help you diversify your funds as per your requirements and helps in achieving your retirement goals, children education, investment in property, business or any smart looking startup ventures

Services we Offer

We offer several services including expert recommendations & suggestions on buying ETF, Mutual Funds, Bonds, Debt securities, Equities, Property invesments and several others

Live Market Data

We provide you live market data for your analysis, review and looking out for quick buying opportunities to help you